The article by [@B7a] proposes that applying batch correction approaches to microarray data from studies with unbalanced designs may inadvertently exaggerate the differences observed. In seeking to illustrate their point, [@B7a] utilized a dataset (GSE61901) from a study we published ([@B11]) and showed that one analysis pipeline utilizing the traditional approach to batch correction (ComBat) yielded over 1000 differentially expressed probesets, while an alternative approach proposed by [@B7a]; utilizing batch as a fixed effect and averaging technical replicates).

recovered 11 differentially expressed probesets.

While we agree with [@B7a] premise that the utilization of ANOVA or empirical-Bayes derived approaches to correct for batch effects may in certain cases overestimate significance, the approach they propose is surprisingly sensitive to differences in how data are preprocessed, specifically the handling of technical replicates. We therefore sought to identify alternate methods that address the points raised by [@B7a]. These efforts yielded three alternative approaches for analyzing microarray data from studies with similar designs to ours, each of which adjusts for technical variation while avoiding the risks that [@B7a] described:

1.  \(i\) Utilize the technical replicates as a random-effect variable in LIMMA.

2.  \(ii\) Utilize the technical replicate as a random variable in a repeated-measures ANOVA.

3.  \(iii\) Utilize a linear mixed-effects model to account for the technical replicate as a random effect while accounting for treatment as a fixed effect.

Each of the aforementioned methodologies is readily accessible through R's base or Bioconductor packages.

[@B7a] referenced a study (GSE61901) we conducted ([@B11]), in which we found significant and biologically relevant differences between the gene expression profiles induced by glatiramer acetate (GA, Copaxone), and the gene expression profiles induced by a generic GA (Glatimer$\documentclass[12pt]{minimal}
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}{}$^{\mathrm{\circledR }}$\end{document}$ Mouse-WG6 microarray chips. Each WG6 chip contains six microarrays, and each of the microarrays containing two physical strips that are to be treated as technical replicates ([@B7]). Because the distribution of the samples on each chip was heavily unbalanced (see [supplementary Table 1](#sup1){ref-type="supplementary-material"} available at *Biostatistics* online), the dataset was initially analysed with ComBat including the treatments as covariates as required by the SVA package ([@B5]) and noted by [@B7a]. The dataset was further analysed using various methods including two-way ANOVA and LIMMA yielding hundreds of differentially expressed probesets between GA and generic.
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In contrast, [@B7a] performed an analysis in which all the technical replicates were averaged. After averaging all technical replicates, [@B7a] utilized the chip ID as a blocking variable in the analysis model, finding 11 probesets that pass FDR cutoff of 0.05. Another approach is to utilize the duplicateCorrelation feature recommended by LIMMA's authors for handling technical replicates from Illumina WG-6 BeadChips ([@B7]). While averaging technical replicates has been suggested in the literature in cases where a t-test or two-way ANOVA will be utilized for downstream analysis ([@B3]), the utilization of models that can account for both technical as well as biological variation is an alternative approach to maximize power of the statistical test ([@B2]; [@B3]; [@B10]). When GSE61901 is utilized and duplicateCorrelation is applied to account for the technical replicates, we find that the approach proposed by [@B7a] of blocking for batch effect in LIMMA identifies 1474 differentially expressed probesets. Thus, the results of [@B7a] proposed batch correction method differ dramatically depending upon how a dataset is preprocessed.

Upon further investigation, a variety of different preprocessing and batch correction methods all yield far more differentially expressed genes than the method proposed by [@B7a]. [Table 1](#T1){ref-type="table"} reports the results of various analyses we have conducted using a variety of techniques including LIMMA ([@B7], duplicateCorrelation method: [@B8]; [@B10]) and mixed-effects ANOVA that are specifically designed to analyze unbalanced designs without reducing power ([@B1]; [@B6]; [@B9]). Code for these analyses is publicly available at <https://github.com/immuneering/biostat_reply>. Such methods take into account correlations between repeated measurements from the same subject/biological sample. These findings strongly suggest that the differences between GA and generic are robust to changes in batch correction and analysis methodologies, and support the key conclusions of Towfic *and others* (2014).

In summary, we present three different methods for analyzing microarray data that utilize technical replicates while correcting for batch effects. These methods yield consistent results, and therefore represent robust alternatives to traditional batch correction methods in datasets subject to the concerns articulated by [@B7a].
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